Personalization of Therapy for MDS: The Role of Biology, Risk Stratification, and Evolving Therapies
This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Summarize the role of prognostic factors and prognostic scoring systems utilized in MDS
- Discuss the current approaches to diagnostic evaluation, risk assessment, risk-adapted therapy, and supportive care needs for patients with MDS
- Review recent clinical trial data with new combinations or investigational agents in MDS
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
- 0.75 Participation
- 0.78 Nurse
- 0.75 Pharmacist
- 0.75 Physician